Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: Racial differences

Prostate

Volumn 72, Issue 2, 2012, Pages 173-180

  Tang, Ping ^a   Du, Wei ^a   Xie, Keji ^a   Fu, Jingao ^a   Chen, Hui ^a   Yang, Wenjun ^a   Moul, Judd W ^b  

^a GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

prostate cancer; prostate specific antigen; prostate specific antigen velocity; race; young men

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AFRICAN AMERICAN; ARTICLE; CANCER RISK; CHINESE; EUROPEAN AMERICAN; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; VELOCITY;

ADULT; AFRICAN AMERICANS; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 84455162658     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21418     Document Type: Article

References (28)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60 (5): 277-300.
2. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD,. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360 (13): 1310-1319.
3. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A,. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360 (13): 1320-1328.
4. Lane JA, Howson J, Donovan JL, Goepel JR, Dedman DJ, Down L, Turner EL, Neal DE, Hamdy FC,. Detection of prostate cancer in unselected young men: Prospective cohort nested within a randomised controlled trial. BMJ 2007; 335 (7630): 1139.
5. Scales CD Jr, Antonelli J, Curtis LH, Schulman KA, Moul JW,. Prostate-specific antigen screening among young men in the United States. Cancer 2008; 113 (6): 1315-1323.
6. Lei T, Mao WM, Yang HJ, Chen XZ, Lei TH, Wang X, Ying Q, Chen WQ, Zhang SW,. Study on cancer incidence through the Cancer Registry Program in 11 Cities and Counties, China. Zhonghua Liu Xing Bing Xue Za Zhi 2009; 30 (11): 1165-1170.
7. Carroll P, Albertsen PC, Greene K,. et al. Prostate-Specific Antigen Best Practice Statement: 2009 Update. Accessed July 8, 2009.
8. National Comprehensive Cancer Network: NCCN clinical practice guideline in oncology. NCCN stresses importance of PSA testing in high-risk men. Available from. Updated August 10, 2009.
9. Na YQ, Sun G,. Chinese guidelines for the diagnosis and management of urological diseases, Beijing: People's Medical Publishing House; 2009. pp. 47-74.
10. Tang P, Sun L, Uhlman MA, Robertson CN, Polascik TJ, Moul JW,. Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men. BJU Int 2010; [Epub ahead of print].
11. Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB,. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: Results from the Baltimore Longitudinal Study of Aging. Urology 2001; 58 (3): 411-416. (Pubitemid 32816360)
12. Ulmert D, Cronin AM, Bjork T, O'Brien MF, Scardino PT, Eastham JA, Becker C, Berglund G, Vickers AJ, Lilja H,. Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study. BMC Med 2008; 6: 6.
13. Tang P, Sun L, Uhlman MA, Polascik TJ, Freedland SJ, Moul JW,. Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke university experience. Cancer 2010; 116 (20): 4711-4717.
14. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P,. Prostate specific antigen best practice statement: 2009 update. J Urol 2009; 182 (5): 2232-2241.
15. Loeb S, Roehl KA, Catalona WJ, Nadler RB,. Prostate specific antigen velocity threshold for predicting prostate cancer in young men. J Urol 2007; 177 (3): 899-902. (Pubitemid 46223578)
16. Sun L, Moul JW, Hotaling JM, Rampersaud E, Dahm P, Robertson C, Fitzsimons N, Albala D, Polascik TJ,. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. BJU Int 2007; 99 (4): 753-757. (Pubitemid 46439564)
17. Matsuda T, Saika K,. Comparison of time trends in prostate cancer incidence (1973-2002) in Asia, from cancer incidence in five continents, Vols IV-IX. Jpn J Clin Oncol 2009; 39 (7): 468-469.
18. Weinrich MC, Jacobsen SJ, Weinrich SP, Moul JW, Oesterling JE, Jacobson D, Wise R,. Reference ranges for serum prostate-specific antigen in black and white men without cancer. Urology 1998; 52 (6): 967-973. (Pubitemid 28533360)
19. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW,. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 1996; 335 (5): 304-310. (Pubitemid 26362377)
20. Preston DM, Levin LI, Jacobson DJ, Jacobsen SJ, Rubertone M, Holmes E, Murphy GP, Moul JW,. Prostate-specific antigen levels in young white and black men 20-45 years old. Urology 2000; 56 (5): 812-816.
21. Lilja H, Ulmert D, Bjork T, Becker C, Serio AM, Nilsson JA, Abrahamsson PA, Vickers AJ, Berglund G,. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 2007; 25 (4): 431-436. (Pubitemid 350002992)
22. Gilbert SM, Cavallo CB, Kahane H, Lowe FC,. Evidence suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: Review of 36,316 biopsies. Urology 2005; 65 (3): 549-553. (Pubitemid 40386007)
23. Liu ZY, Sun YH, Xu CL, Gao X, Zhang LM, Ren SC,. Age-specific PSA reference ranges in Chinese men without prostate cancer. Asian J Androl 2009; 11 (1): 100-103.
24. He D, Wang M, Chen X, Gao Z, He H, Zhau HE, Wang W, Chung LW, Nan X,. Ethnic differences in distribution of serum prostate-specific antigen: A study in a healthy Chinese male population. Urology 2004; 63 (4): 722-726. (Pubitemid 38479417)
25. Ku JH, Ahn JO, Lee CH, Lee NK, Park YH, Byun SS, Kwak C, Lee SE,. Distribution of serum prostate-specific antigen in healthy Korean men: Influence of ethnicity. Urology 2002; 60 (3): 475-479. (Pubitemid 35292177)
26. Loeb S, Carter HB, Schaeffer EM, Kettermann A, Ferrucci L, Metter EJ,. Distribution of PSA velocity by total PSA levels: Data from the Baltimore Longitudinal Study of Aging. Urology 2011; 77 (1): 143-147.
27. Tang J, Yang J,. Etiopathogenesis of benign prostatic hypeprlasia. Indian J Urol 2009; 25 (3): 312-317.
28. Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI, Trock BJ, Metter EJ,. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006; 98 (21): 1521-1527. (Pubitemid 44680903)